Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HKPD
HKPD logo

HKPD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.740
Open
0.740
VWAP
0.72
Vol
13.32K
Mkt Cap
17.15M
Low
0.680
Amount
9.55K
EV/EBITDA(TTM)
--
Total Shares
23.50M
EV
18.53M
EV/OCF(TTM)
--
P/S(TTM)
--
Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.
Show More

Events Timeline

(ET)
2026-03-27
15:30:00
Cellyan Biotechnology Files to Sell 12.5M Class A Ordinary Shares
select
2025-01-15 (ET)
2025-01-15
10:42:18
Hong Kong Pharma opens at $3.50, IPO priced at $4 per share
select

News

seekingalpha
8.5
01-16seekingalpha
Cellyan Biotechnology (HKPD) Receives Nasdaq Warning for Non-Compliance with $1 Minimum Bid Price
  • Compliance Warning: On January 12, 2026, Cellyan Biotechnology received a Nasdaq notification for non-compliance due to its shares trading below $1 for 30 consecutive business days from November 26, 2025, to January 9, 2026, potentially undermining investor confidence.
  • Compliance Period: The company has been granted a 180-day compliance period until July 13, 2026, to regain compliance, and may consider measures such as a reverse stock split, indicating its commitment to preserving shareholder value.
  • Additional Grace Period: Cellyan may qualify for an additional 180-day grace period, providing further time to adjust its stock price, reflecting management's flexibility in addressing market challenges.
  • Market Reaction: This notification may raise investor concerns about Cellyan's future performance, impacting its market image and financing capabilities, which could have potential implications for the company's long-term strategy.
Globenewswire
7.0
01-16Globenewswire
Cellyan Biotechnology Receives Nasdaq Notification for Share Price Below $1
  • Compliance Notification: Cellyan Biotechnology received a Nasdaq notification on January 12, 2026, indicating that its Class A ordinary shares had closed below the $1 minimum bid price for 30 consecutive trading days from November 26, 2025, to January 9, 2026, potentially impacting the company's financing capabilities.
  • Compliance Period Established: Under Nasdaq rule 5810(c)(3)(A), the company has a compliance period of 180 days until July 13, 2026, to regain compliance; if the share price reaches $1 and remains for ten consecutive trading days, compliance will be restored, ensuring continued listing.
  • Potential Reverse Split: If compliance is not regained within the period, the company may need to implement measures such as a reverse stock split during a second 180-day grace period to meet Nasdaq listing standards, increasing future financial and operational risks.
  • Ongoing Listing Impact: Although the notification does not immediately affect the listing of the company's Class A ordinary shares, failure to regain compliance in a timely manner could lead to more severe market challenges, affecting investor confidence and shareholder value.
Globenewswire
9.0
2025-12-17Globenewswire
HKPD Approves Major Capital Restructuring at 2025 Annual Meeting
  • Board Re-election: At the 2025 annual meeting, shareholders unanimously re-elected five directors, ensuring continuity and stability in governance, which is expected to enhance investor confidence.
  • Accounting Firm Appointment: Shareholders ratified the appointment of Onestop Assurance PAC as the independent registered public accounting firm for fiscal year 2026, ensuring financial transparency and compliance, which will help improve market credibility.
  • Capital Structure Adjustment: The company increased its authorized share capital from $100,000 to $1,000,000, expanding the number of ordinary shares from 100 million to 1 billion, a move that will provide greater flexibility for future financing and expansion.
  • Share Consolidation and Name Change: By implementing a reverse share split and share consolidation, the company will change its name to “Cellyan Biotechnology Co., Ltd,” aiming to enhance brand image and attract more investor attention.
Newsfilter
2.0
2025-12-17Newsfilter
HKPD Restructures Capital Structure Through Shareholder Meeting Approvals
  • Board Re-election: At the 2025 annual meeting, shareholders unanimously approved the re-election of five directors, ensuring continuity and stability in corporate governance, which is expected to enhance investor confidence.
  • Accounting Firm Ratification: Shareholders confirmed the appointment of Onestop Assurance PAC as the independent registered public accounting firm for fiscal year 2026, which will improve financial transparency and enhance the credibility of external audits.
  • Capital Increase: The company will increase its authorized share capital from $100,000 to $1,000,000, expanding the number of ordinary shares from 100 million to 1 billion, aimed at providing greater flexibility for future financing and expansion.
  • Name Change and Share Restructuring: The company will change its name from
Benzinga
9.0
2025-08-26Benzinga
Serina Therapeutics Stock Rises Over 25%; Check Out 20 Stocks Making Moves in Premarket Trading
  • Serina Therapeutics Surge: Shares of Serina Therapeutics Inc rose 25.3% to $7.07 in pre-market trading following positive FDA feedback on SER-252.

  • Other Notable Gainers: Invivyd Inc shares increased by 84.1%, Steakholder Foods Ltd gained 62.4%, and Beneficient saw a rise of 55% in pre-market trading.

  • Significant Losers: ESSA Pharma Inc experienced a sharp decline of 59.8%, while Femasys Inc fell 42.8% after announcing a public offering.

  • Market Trends: Overall, several stocks showed significant fluctuations in pre-market trading, with both notable gains and losses reported.

Benzinga
9.0
2025-05-19Benzinga
Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
  • Novavax Vaccine Approval: Novavax, Inc. shares surged 16.6% to $7.84 in pre-market trading following the FDA's conditional approval of its COVID-19 vaccine for specific populations.

  • Market Movements: Several stocks experienced significant pre-market fluctuations, with Healthcare Triangle, Inc. rising 59.2%, while Affimed N.V. saw a decline of 35.5%.

Valuation Metrics

The current forward P/E ratio for Cellyan Biotechnology Co Ltd (HKPD.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Cellyan Biotechnology Co Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Whales Holding HKPD

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cellyan Biotechnology Co Ltd (HKPD) stock price today?

The current price of HKPD is 0.73 USD — it has increased 4.29

What is Cellyan Biotechnology Co Ltd (HKPD)'s business?

Cellyan Biotechnology Co Ltd is an investment holding company mainly engaged in the over the counter (OTC) pharmaceutical business. The Company mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.

What is the price predicton of HKPD Stock?

Wall Street analysts forecast HKPD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for HKPD is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cellyan Biotechnology Co Ltd (HKPD)'s revenue for the last quarter?

Cellyan Biotechnology Co Ltd revenue for the last quarter amounts to 13.04 USD, decreased -24.10

What is Cellyan Biotechnology Co Ltd (HKPD)'s earnings per share (EPS) for the last quarter?

Cellyan Biotechnology Co Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Cellyan Biotechnology Co Ltd (HKPD). have?

Cellyan Biotechnology Co Ltd (HKPD) has 27 emplpoyees as of April 19 2026.

What is Cellyan Biotechnology Co Ltd (HKPD) market cap?

Today HKPD has the market capitalization of 17.15M USD.